Understanding heart problems caused by cancer treatments
Unraveling Proteasome Inhibitor-Induced Cardiovascular Toxicity through Integrative Multiomics
['FUNDING_R01'] · STANFORD UNIVERSITY · NIH-11023940
This study is looking at how certain cancer treatments called proteasome inhibitors might affect heart health, and it's for patients who are receiving these therapies; researchers want to understand the heart changes caused by these drugs so they can help make cancer treatments safer for everyone.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STANFORD UNIVERSITY (nih funded) |
| Locations | 1 site (STANFORD, UNITED STATES) |
| Trial ID | NIH-11023940 on ClinicalTrials.gov |
What this research studies
This research investigates how proteasome inhibitors, a type of cancer treatment, can lead to heart-related side effects. Using advanced techniques like CRISPR technology and single-cell RNA sequencing, the study aims to identify the molecular changes in heart cells caused by these drugs. By examining both mouse models and human stem cells, researchers hope to uncover the mechanisms behind cardiovascular toxicity and explore potential ways to prevent it. The ultimate goal is to improve the safety of cancer therapies for patients who need them.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients undergoing treatment with proteasome inhibitors, particularly those with hematologic malignancies.
Not a fit: Patients not receiving proteasome inhibitors or those without cardiovascular concerns may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer cancer treatments with fewer heart-related side effects.
How similar studies have performed: Other research has shown promise in understanding drug-induced toxicity through similar molecular approaches, indicating potential for success in this area.
Where this research is happening
STANFORD, UNITED STATES
- STANFORD UNIVERSITY — STANFORD, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WU, JOSEPH C. — STANFORD UNIVERSITY
- Study coordinator: WU, JOSEPH C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.